Last quarter (Q3 2023), Medicine Man Technologies's total revenue was $42.94M, an increase of Infinity% from the same quarter last year. In Q3, Medicine Man Technologies's net income was $-1.87M. See Medicine Man Technologies’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 138.61M	$ 142.95M	$ 116.93M	$ 24.00M	$ 10.62M	$ 7.92M
Credit Losses Provision	-	-	-	-	-	-
Non Interest Expense	$ 77.90M	$ 72.17M	$ 98.01M	-	-	-
Incomefrom Associatesand Other Participating Interests	-	-	-	-	-	-
Special Income Charges	$ -90.49M	$ -8.01M	$ -59.07M	$ 1.46M	$ 1.63M	$ 1.31M
Pretax Income	$ -13.64M	$ -3.57M	$ 18.92M	$ -20.32M	$ -17.56M	$ 1.53M
Tax Provision	$ 18.89M	$ 14.90M	$ 4.40M	$ -899.11K	$ -582.93K	$ 582.93K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ 36.96M	$ -26.27M	$ 7.17M	$ -19.42M	$ -16.98M	$ 948.91K
Basic EPS	$ 1.78M	$ -0.49	$ 0.17	$ -0.47	$ -0.50	$ 0.04
Diluted EPS	$ -0.73	$ -0.49	$ -0.06	$ -0.47	$ -0.50	$ 0.03
Basic Average Shares	$ 257.21M	$ 53.64M	$ 43.34M	$ 41.22M	$ 33.74M	$ 25.12M
Diluted Average Shares	$ 302.99M	$ 53.64M	$ 101.37M	$ 41.22M	$ 33.74M	$ 27.77M
Dividend Per Share	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Interest Income After Provision For Loan Loss	$ -30.80M	$ -30.14M	$ -7.01M	-	-	-
Net Income From Continuing And Discontinued Operation	$ 41.83M	$ -18.47M	$ 14.52M	$ -19.42M	$ -16.98M	$ 948.91K
Normalized Income	$ 2.89M	$ 9.88M	-	$ -21.90M	$ -13.17M	$ 423.01K
Total Money Market Investments	-	-	-	-	-	-
Ebit	$ -17.29M	-	$ 18.92M	$ -20.27M	$ -13.46M	$ 652.24K
Ebitda	$ 3.13M	-	$ 27.49M	$ -19.80M	$ -13.40M	$ 734.20K

Currency in USD

Medicine Man Technologies Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing